Mov Disord Vol 35, Suppl 1 Archives - Page 93 of 149 - MDS Abstracts

MDS Virtual Congress 2020
Do dreams tell the future? Dream content analysis as a predictor of cognitive deterioration in Parkinson’s Disease
P. Bugalho, F. Ladeira, R. Barbosa, J. Marto, C. Borbinha, L. Conceição, M. Saraiva, M. Salavisa, B. Meira, M. Fernandes (Lisboa, Portugal)
Objective: Assess the predicitive value of dream content for cognitive dysfuncion progression in Parkinson's Disease (PD). Background: PD patients frequently complain of vivid dreams. Cross-sectional…
MDS Virtual Congress 2020
Repetitive transcranial magnetic stimulation (rTMS) fails to improve cognition in patients with Parkinson’s disease: a meta-analysis of randomized controlled trials
P. He, L. Wang, J. Chen, Y. Zhang, Y. Gao, Q. Xu, Y. Qiu, H. Cai, Y. Li, Z. Huang, S. Feng, J. Zhao, G. Ma, K. Nie, L. Wang (Guangzhou, China)
Objective: This study aimed to evaluate the effects of rTMS for improving cognition of PD patients. Background: Up to 20%–50% of patients with Parkinson’s disease…
MDS Virtual Congress 2020
Task based profiles of language impairment in Parkinson’s Disease
A. Lowit, M. Roheger, E. Kalbe, T. Thies, J. Steffen, M. Barbe (Glasgow, United Kingdom)
Objective: This study aimed to add to our understanding of language impairment in people with Parkinson's Disease (PwPD). Background: Language difficulties are increasingly reported in…
MDS Virtual Congress 2020
Improved verb use in Parkinson’s disease following intensive voice treatment
A. Ramage, C. Fox, A. Halpern, L. Ramig (Durham, NH, USA)
Objective: To identify changes in language production secondary to voice treatment in speakers with Parkinson’s disease (PD). Background: Given the role of voice in language…
MDS Virtual Congress 2020
Vascular, inflammatory and metabolic risk factors in relation to dementia in Parkinson’s disease patients with type 2 diabetes mellitus
Q. Wang (Guangzhou, China)
Objective: Identifying the risk factors of dementia in patients with both Parkinson’s disease (PD) and type 2 diabetes mellitus (DM) (PD-DM) is clinically relevant and…
MDS Virtual Congress 2020
The ADNPC-RS: a risk score that identifies Lewy body disease individuals at risk for developing concomitant Alzheimer’s pathology
D. Dai, T. Tropea, J. Robinson, E. Suh, H. Hurtig, D. Weintraub, V. Van Deerlin, E. Lee, J. Trojanowski, A. Chen-Plotkin (Philadelphia, PA, USA)
Objective: To identify which common genetic variants that confer risk for Alzheimer’s disease (AD) also predict the development of concomitant AD pathology in patients with…
MDS Virtual Congress 2020
Survival in Parkinson’s Disease and Association with MAPT and APOE
S. Kola, S. Armasu, D. Weis, O. Ross, D. Maraganore, A. Hassan (Rochester, MN, USA)
Objective: To assess survival in a large cohort of Parkinson's disease (PD) patients, and to determine if survival correlates with MAPT and APOE gene variants.…
MDS Virtual Congress 2020
Human induced pluripotent stem cells (iPSCs) as a model for the study of neural development in Parkinson’s Disease patients carrying GBA mutations
F. Motolese, A. Casamassa, A. Vescovi, V. Di Lazzaro, J. Rosati, M. Marano (Rome, Italy)
Objective: The aim of this study is to evaluate in vitro development of human induced pluripotent stem cells (iPSCs) [1] derived from fibroblasts of Parkinson’s…
MDS Virtual Congress 2020
Characterizing Global Cohorts with Monogenic Parkinson’s Disease
E.J Vollstedt, S. Schaake, M. Kasten, K. Lohmann, C. Klein (Lübeck, Germany)
Objective: To clinically and genetically characterize a global sample of subjects with monogenic Parkinson’s disease (mPD) and unaffected mutation carriers. Background: Publications on patients with…
MDS Virtual Congress 2020
Auxilin knockout mice: a model for Parkinsonism with dopamine dysregulation and synucleinopathy
V. DJ, S. Chandra (New Haven, CT, USA)
Objective: To evaluate the role of auxilin in the pathogenesis of Parkinson’s disease (PD). Background: Auxilin or DNAJC6, a brain-specific co-chaperone plays central role in…